Literature DB >> 22608339

Scaling up interventions to achieve global tuberculosis control: progress and new developments.

Mario Raviglione1, Ben Marais, Katherine Floyd, Knut Lönnroth, Haileyesus Getahun, Giovanni B Migliori, Anthony D Harries, Paul Nunn, Christian Lienhardt, Steve Graham, Jeremiah Chakaya, Karin Weyer, Stewart Cole, Stefan H E Kaufmann, Alimuddin Zumla.   

Abstract

Tuberculosis is still one of the most important causes of death worldwide. The 2010 Lancet tuberculosis series provided a comprehensive overview of global control efforts and challenges. In this update we review recent progress. With improved control efforts, the world and most regions are on track to achieve the Millennium Development Goal of decreasing tuberculosis incidence by 2015, and the Stop TB Partnership target of halving 1990 mortality rates by 2015; the exception is Africa. Despite these advances, full scale-up of tuberculosis and HIV collaborative activities remains challenging and emerging drug-resistant tuberculosis is a major threat. Recognition of the effect that non-communicable diseases--such as smoking-related lung disease, diet-related diabetes mellitus, and alcohol and drug misuse--have on individual vulnerability, as well as the contribution of poor living conditions to community vulnerability, shows the need for multidisciplinary approaches. Several new diagnostic tests are being introduced in endemic countries and for the first time in 40 years a coordinated portfolio of promising new tuberculosis drugs exists. However, none of these advances offer easy solutions. Achievement of international tuberculosis control targets and maintenance of these gains needs optimum national health policies and services, with ongoing investment into new approaches and strategies. Despite growing funding in recent years, a serious shortfall persists. International and national financial uncertainty places gains at serious risk. Perseverance and renewed commitment are needed to achieve global control of tuberculosis, and ultimately, its elimination.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22608339     DOI: 10.1016/S0140-6736(12)60727-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  103 in total

1.  A new free-cost e-service supporting clinicians to manage their difficult-to-treat TB cases: the ERS-WHO TB consilium.

Authors:  Lia D'Ambrosio; Marina Tadolini; Rosella Centis; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

2.  School-based interventions to promote early diagnosis of TB: realising the promise of community-based screening?

Authors:  Katharina Kranzer; Elizabeth L Corbett
Journal:  Public Health Action       Date:  2012-12-21

3.  Assessment of Mycobacterium tuberculosis pantothenate kinase vulnerability through target knockdown and mechanistically diverse inhibitors.

Authors:  B K Kishore Reddy; Sudhir Landge; Sudha Ravishankar; Vikas Patil; Vikas Shinde; Subramanyam Tantry; Manoj Kale; Anandkumar Raichurkar; Sreenivasaiah Menasinakai; Naina Vinay Mudugal; Anisha Ambady; Anirban Ghosh; Ragadeepthi Tunduguru; Parvinder Kaur; Ragini Singh; Naveen Kumar; Sowmya Bharath; Aishwarya Sundaram; Jyothi Bhat; Vasan K Sambandamurthy; Christofer Björkelid; T Alwyn Jones; Kaveri Das; Balachandra Bandodkar; Krishnan Malolanarasimhan; Kakoli Mukherjee; Vasanthi Ramachandran
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

4.  Minding the gaps: metabolomics mends functional genomics.

Authors:  Kyu Rhee
Journal:  EMBO Rep       Date:  2013-10-01       Impact factor: 8.807

5.  Molecular insights into the binding of coenzyme F420 to the conserved protein Rv1155 from Mycobacterium tuberculosis.

Authors:  Ellene H Mashalidis; Apostolos G Gittis; Aurelie Tomczak; Chris Abell; Clifton E Barry; David N Garboczi
Journal:  Protein Sci       Date:  2015-03-10       Impact factor: 6.725

6.  1,4-azaindole, a potential drug candidate for treatment of tuberculosis.

Authors:  Monalisa Chatterji; Radha Shandil; M R Manjunatha; Suresh Solapure; Vasanthi Ramachandran; Naveen Kumar; Ramanatha Saralaya; Vijender Panduga; Jitendar Reddy; K R Prabhakar; Sreevalli Sharma; Claire Sadler; Christopher B Cooper; Khisi Mdluli; Pravin S Iyer; Shridhar Narayanan; Pravin S Shirude
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

7.  Insight into Structure-Function Relationships and Inhibition of the Fatty Acyl-AMP Ligase (FadD32) Orthologs from Mycobacteria.

Authors:  Valérie Guillet; Ségolène Galandrin; Laurent Maveyraud; Simon Ladevèze; Vincent Mariaule; Cécile Bon; Nathalie Eynard; Mamadou Daffé; Hedia Marrakchi; Lionel Mourey
Journal:  J Biol Chem       Date:  2016-02-21       Impact factor: 5.157

8.  Epidemiology of antituberculosis drug resistance in Saudi Arabia: findings of the first national survey.

Authors:  Sahal Al-Hajoj; Bright Varghese; Mohammed M Shoukri; Ruba Al-Omari; Mais Al-Herbwai; Fahad Alrabiah; Abdulrahman A Alrajhi; Naila Abuljadayel; Sahar Al-Thawadi; Alimuddin Zumla; Matteo Zignol; Mario C Raviglione; Ziad Memish
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

Review 9.  Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action.

Authors:  William A Wells; Catharina C Boehme; Frank G J Cobelens; Colleen Daniels; David Dowdy; Elizabeth Gardiner; Jan Gheuens; Peter Kim; Michael E Kimerling; Barry Kreiswirth; Christian Lienhardt; Khisi Mdluli; Madhukar Pai; Mark D Perkins; Trevor Peter; Matteo Zignol; Alimuddin Zumla; Marco Schito
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

Review 10.  Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.

Authors:  Stephen D Lawn; Peter Mwaba; Matthew Bates; Amy Piatek; Heather Alexander; Ben J Marais; Luis E Cuevas; Timothy D McHugh; Lynn Zijenah; Nathan Kapata; Ibrahim Abubakar; Ruth McNerney; Michael Hoelscher; Ziad A Memish; Giovanni Battista Migliori; Peter Kim; Markus Maeurer; Marco Schito; Alimuddin Zumla
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.